However, abnormal activation of the PI3K/AKT and RAS/ERK signaling pathways usually coexists and synergistically leads to trastuzumab resistance, and the suppression of a single pathway is not always effective in BC patients resistant to trastuzumab. This evidence concerns the gene AKT1 and breast cancer.